Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8150 of 8900 results

  1. Intraoperative fluorescence angiography for the evaluation of coronary artery bypass graft patency (IPG98)

    We have moved interventional procedures guidance 98 to become HealthTech guidance 60. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. Sacral nerve stimulation for faecal incontinence (IPG99)

    We have moved interventional procedures guidance 99 to become HealthTech guidance 61. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Gastroparesis

    All NICE products on gastroparesis. Includes any advice.

    Topic page

  4. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued Reference number: GID-HST10019

    Highly specialised technologies guidance
    Discontinued

  5. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 13 February 2026.

    Technology appraisal guidance
    In consultation

  6. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

    Technology appraisal guidance
    In consultation

  7. Smoking and tobacco

    All NICE products on smoking and tobacco. Includes any guidance and quality standards.

    Topic page

  8. Sunlight exposure

    All NICE products on sunlight exposure. Includes any guidance.

    Topic page

  9. Mental health and wellbeing

    All NICE products on mental health and wellbeing. Includes any guidance and quality standards.

    Topic page

  10. Alcohol

    All NICE products on alcohol. Includes any guidance and quality standards.

    Topic page

  11. Behaviour change

    All NICE products on behaviour change. Includes any guidance and quality standards.

    Topic page

  12. Physical activity

    All NICE products on physical activity. Includes any guidance and quality standards.

    Topic page

  13. Sepsis (QS161)

    November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  14. Neonatal specialist care (QS4)

    This quality standard has been withdrawn. Specialist neonatal care is covered in the NICE quality standards for specialist neonatal respiratory care for babies born pre-term, developmental follow-up of children and young people born preterm, maternal and child nutrition and postnatal care.

    Withdrawn quality standard

  15. Epilepsy in adults (QS26)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Withdrawn quality standard

  16. Epilepsy in children and young people (QS27)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Withdrawn quality standard

  17. Venous thromboembolism in adults: diagnosis and management (QS29)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Withdrawn quality standard

  18. Venous thromboembolism in adults: reducing the risk in hospital (QS3)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Withdrawn quality standard

  19. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Withdrawn quality standard

  20. Obesity in adults: prevention and lifestyle weight management programmes (QS111)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  21. Dementia: support in health and social care (QS1)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Withdrawn quality standard

  22. Obesity: clinical assessment and management (QS127)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  23. Smoking: supporting people to stop (QS43)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Withdrawn quality standard

  24. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Withdrawn quality standard

  25. Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  26. Nutrition: improving maternal and child nutrition (QS98)

    January 2025: This quality standard has been stood down. Quality statements on maternal and child nutrition can be found in the NICE quality standards on antenatal care and postnatal care.

    Withdrawn quality standard

  27. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Withdrawn quality standard

  28. Glaucoma in adults (QS7)

    This quality standard has been updated and replaced by NICE quality standard 180.

    Withdrawn quality standard

  29. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  30. Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)

    Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE HealthTech guidance 608. 

    Withdrawn guidance

  31. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  32. Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Withdrawn advice

  33. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

    Withdrawn advice

  34. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  35. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Withdrawn advice

  36. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

    Withdrawn advice

  37. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  38. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  39. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Withdrawn advice

  40. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  41. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Withdrawn advice

  42. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  43. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Withdrawn guidance

  44. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  45. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  46. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  47. Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

    The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

    Withdrawn guidance

  48. Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (TA295)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA421.

    Withdrawn guidance

  49. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Withdrawn guidance

  50. Ocriplasmin for treating vitreomacular traction (TA297)

    We have withdrawn this guidance. Inceptua has stopped marketing Ocriplasmin (Jetrea) and its marketing authorisation has been withdrawn.

    Withdrawn guidance